GRAL · GRAIL, Inc.
$143.26
+10.70 (+8.07%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$5.67B
Shares
44.67M
Volume · Oct 2
875.34K
Avg daily vol (3M)
902.09K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$143.26
Open$135.52
Day$134.45–143.50
52W close$43.03–143.26
Avg vol 30d1.2M
Short int8.6M · 19.2% float · 12.7d
Short vol49%
Last earningsAug 5, 2026
DataJun 2024–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 3 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$165.26M
Trailing 12 months
Net income (TTM)
−$391.59M
Trailing 12 months
Revenue growth YoY
+25.7%
Year over year
Operating margin
-338.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$55.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.4%
Year over year · more shares
Price change (1Y)
+121.3%
Trailing year
Short interest
19.2%
Latest settlement · 12.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+95%
above
Price vs 50-day avg
+70%
above
RSI (14)
82
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+78%
trailing
6-month return
+214%
trailing
YTD return
+67%
this year
Relative strength
+202%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $84 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
2 of 380 funds reported for Sep 30 · net +6 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.18% of float · ▲ +0.6% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
380 holders — mid 2-yr range
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-299.9M
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue growth
· the year
22% – 32%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+95%
Bullish
Price vs 50-day avg
+70%
Bullish
RSI (14)
82
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $84 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
2 of 380 funds reported for Sep 30 · net +6 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.18% of float · ▲ +0.6% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
380 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $43
Now $143 · 100%
Range high $143
vs 200-day avg +95%
vs 50-day avg +70%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$90.3M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -110.25M
+34.58M Amortization of intangible assets
+19.56M Stock-based compensation
+25.42M Intangible and other assets impairment
+4.11M Depreciation
-56.46M Benefit from income taxes
-7.23M Interest income
+0K Restructuring
= Adjusted EBITDA -90.27M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$5.67B | +67.4% | +17.2% | — | 19.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | +12.9% | +77.8% | +214.0% | +2.2% | +67.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +13.1% | +78.3% | +201.8% | +1.3% | +54.5% |
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
12 filings
11 filers
Visit website
Investor relations